ArticleScientific reports2019
The association analysis between HLA-A*26 and Behçet's disease.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab.Internal medicine (Tokyo, Japan) · 2026Article
- [Role of HLA genetic variants in autoimmune diseases].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Saccular common iliac artery aneurysm associated with HLA-A26 and HLA-B27 in a young adult patient: a surgical case report and literature review.General thoracic and cardiovascular surgery cases · 2026Article
- High Resolution HLA-A, HLA-B, and HLA-C Allele Frequencies in Romanian Hematopoietic Stem Cell Donors.International journal of molecular sciences · 2024Article
- Article
- Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.Frontiers in immunology · 2023Review
- The complex HLA-E-nonapeptide in Behçet disease.Frontiers in immunology · 2023Article
- Natural LILRB1 D1-D2 variants show frequency differences in populations and bind to HLA class I with various avidities.Immunogenetics · 2022Article
- Association of long non-coding RNAs NEAT1, and MALAT1 expression and pathogenesis of Behçet's disease among Egyptian patients.Saudi journal of biological sciences · 2022Article
- The Immunogenetics of Behcet's Disease.Advances in experimental medicine and biology · 2022Article
- Epidemiologic and Etiological Features of Korean Patients With Behçet's Disease.Journal of rheumatic diseases · 2021Review
- Current research status of HLA in immune-related diseases.Immunity, inflammation and disease · 2021Review
- Behçet disease, new insights in disease associations and manifestations: a next-generation sequencing study.Clinical and experimental immunology · 2021Article
- Critical Role of Gut Microbiota and Epigenetic Factors in the Pathogenesis of Behçet's Disease.Frontiers in cell and developmental biology · 2021Review
- Article
- Past and Present Behçet's Disease Animal Models.Current drug targets · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The strongest genetic risk factor of Behçet's disease (BD) is HLA-B*51. Our group previously reported that HLA-A*26 is independently associated with the risk of the onset of BD apart from HLA-B*51. Here, we re-evaluated the association between HLA-A*26 and BD in the Japanese population. We also performed a comprehensive literature search and meta-analyzed the extracted published data concerning the relationship between HLA-A*26 and BD to estimate the odds ratio (OR) of HLA-A*26 to BD. In this study, we genotyped 611 Japanese BD patients and 2,955 unrelated ethnically matched healthy controls. Genotyping results showed that the phenotype frequency of HLA-A*26 was higher in BD patients than in controls (OR = 2.12, 95% CI: 1.75-2.56). Furthermore, within the HLA-B*51-negative populations, the phenotype frequency of HLA-A*26 was significantly higher in BD patients than in controls (OR = 3.10, 95% CI: 2.43-3.95). Results obtained from meta-analysis combined with our data showed that the modified OR of HLA-A*26 became 1.80 (95% CI:1.58-2.06), whereas within the HLA-B*51-negative population, the modified OR became 4.02 (95% CI: 2.29-7.05). A subgroup analysis arranged by the geographical regions showed HLA-A*26 is in fact associated with the onset of BD in Northeast Asia (OR = 2.11, 95% CI: 1.75-2.56), but not in the Middle East or in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.